Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Esperion Therapeutics Inc shares valued at $106 were sold by Warren Eric on Apr 17 ’25. At $0.98 per share, Warren Eric sold 108 shares. The insider’s holdings dropped to 370,218 shares worth approximately $0.44 million following the completion of this transaction.
Also, Halladay Benjamin sold 8 shares, netting a total of over 8 in proceeds. Following the sale of shares at $0.96 each, the insider now holds 481,702 shares.
Before that, Halladay Benjamin had added 8 shares to its account. In a trade valued at $8, the Officer bought Esperion Therapeutics Inc shares for $0.96 each.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
On last trading session,, Esperion Therapeutics Inc [NASDAQ: ESPR] plunged -0.83% to $1.20. The stock’s lowest price that day was $1.18, but it reached a high of $1.21 in the same session. During the last five days, there has been a surge of approximately 3.45%. Over the course of the year, Esperion Therapeutics Inc shares have dropped approximately -45.45%.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
RSI (Relative Strength Index) is 65.79 on the 14-day chart, showing neutral technical sentiment.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -3.52 million shares to 26.34 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 29.86 million shares. A decline of -13.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.35 of the overall float, the days-to-cover ratio (short ratio) decline to 4.35.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, up nearly 561.16% from the previous closing price of $1.21. Analysts anticipate Esperion Therapeutics Inc stock to reach 8 by 2025, with the lowest price target being 8. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
